← Back to patent-cliff list
Zabopegdutide
Tier C — Watch / tradeZabopegdutide
D&D Pharmatech
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R, GCGR
Indications (approved)：Overweight, Non-alcoholic steatohepatitis, Obesity, Type 2 diabetes
Regional status
US
Phase II
2024-06-13
EU
-
China
Phase I
2024-12-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zabopegdutide?
Approved indications include: Overweight, Non-alcoholic steatohepatitis, Obesity, Type 2 diabetes.
When does the Zabopegdutide patent expire?
No public expiry year is available for Zabopegdutide yet; this page updates once verified.
How do I get a quote for Zabopegdutide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01